title: Italian Survey on Prevalence and Disease Management of Chronic Heart Failure and Chronic Obstructive Pulmonary Disease comorbidity in ambulatory patients. SUSPIRIUM study rationale and design.
abstract: BACKGROUND
  Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are leading causes of morbidity and mortality worldwide. Through shared risk factors and pathophysiological mechanisms, CHF and COPD frequently coexist. The concurrent disease has important therapeutic implications and independently predicts worsened mortality, impaired functional status, and health service use. However, assessment of the comorbidity varies widely according to the population studied, diagnostic criteria and measurement tools applied. Both syndromes have been studied extensively but largely separately, mostly in the domain of the pulmonologist for COPD and in the domain of the cardiologist for CHF.
  The aim of the study is to evaluate in an Italian outpatients setting (10 cardiology and 10 pulmonology centers from the same institution) the prevalence, clinical profile and the routine diagnostic, functional and therapeutic work-up applied by cardiologists and pulmonologists in the presence/suspicion of concurrent disease in patients in a stable phase of their disease. For this purpose, CHF and COPU outpatients will be enrolled in a multicenter, nationwide, prospective observational study. Risk estimation of comorbidity will be based on suspected, documented or patient-reported diagnosis of COPD/CHF. In the absence of documented concurrent diagnosis, each specialist will describe the diagnostic, functional and therapeutic work-up applied.
  
  
  CONCLUSIONS
  The design of the study focused on the diagnostic validation of the CHF-COPD comorbidity aims to provide relevant new information on the assessment of the coexistent condition in the cardiac and pulmonary outpatients setting and on specialty-related different diagnostic and therapeutic strategies of comorbidity utilized in real life clinical practice. The symptomatic and prognostic benefits resulting from a combined approach to CHF/COPD could outweigh those attainable by treating either condition alone.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Griffo
authors.forename: Antonio
authors.initials: A
authors.lastname: Spanevello
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Temporelli
authors.forename: Pompilio
authors.initials: P
authors.lastname: Faggiano
authors.forename: Mauro
authors.initials: M
authors.lastname: Carones
authors.forename: Giovanna
authors.initials: G
authors.lastname: Magni
authors.forename: Nicolino
authors.initials: N
authors.lastname: Ambrosino
authors.forename: Luigi
authors.initials: L
authors.lastname: Tavazzi
mesh_terms: D023181:Antimicrobial Cationic Peptides; D002908:Chronic Disease; D015897:Comorbidity; D019538:Health Care Surveys; D006333:Heart Failure / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D007558:Italy / Q000453:epidemiology; D018579:Patient Selection; D010455:Peptides; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology* / Q000628:therapy
chemical_list: D023181:Antimicrobial Cationic Peptides; D010455:Peptides; C007629:esein